abstract |
The present invention relates to the use of cannabidiol (CBD) and an anti-epileptic drug (AED), brivaracetam (BRV), for the treatment of seizures associated with epilepsy syndromes. In particular the types of seizures treated include atonic, tonic, tonic-clonic, and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. |